Multimodality treatment of non‐small cell lung cancer: Response to cisplatin, VP‐16, and 5‐FU chemotherapy and to surgery and radiation therapy

Twenty-one patients with unresectable non-small cell lung cancer (NSCLC), 11 with stage III M(o), five with malignant pleural effusion, and five with a single resectable metastasis were treated with multimodality therapy. All received two to three cycles of preoperative chemotherapy with a new sequential combination of cisplatin (50 mg/m² IV x 1) followed by 5-FU infusion (40 mg/m²/hr x 72) and etoposide (80 mg/m²/day x 3). Thirteen of 21 (62%) had a partial response, and three (14%) had a minor response to chemotherapy. Of the 19 who underwent surgical exploration, 17 were confirmed to have NSCLC. Ten patients with NSCLC and one with choriocarcinoma were rendered disease free by resection of the primary tumor and lymph nodes. Six received intra-and/or perioperative interstitial therapy with ¹²⁵I and/or ¹⁹²Ir. Another patient was treated with ³²P. Postoperative external radiotherapy was administered in 15 patients, and adjuvant chemotherapy was administered in ten. This multimodality therapy was well tolerated, safe, and highly effective, resulting in excellent palliation even in patients with pleural effusion and metastasis. The most promising results were in unresectable stage III M(o) with a partial response rate of 82% following neoadjuvant chemotherapy and a complete response rate of 73% after surgery. In this group, median survival has not yet been reached and will exceed 12 months.